$PFLT

PennantPark Floating Rate Capital Ltd. (NYSE:PFLT) Short Interest Up 36.3% in January

PennantPark Floating Rate Capital Ltd. (NYSE:PFLT) experienced a 36.3% increase in short interest in January, reaching 1,663,625 shares, which represents 1.7% of its stock. The short-interest ratio is 1.4 days based on its average daily volume. Analyst sentiment is mixed, with some recommending a "moderate buy" and others a "sell," leading to an average "Moderate Buy" rating and a $10.50 target price.

Original reporting
MarketBeat · MarketBeat
Published Feb 2, 2026, 5:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 2, 2026, 6:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PennantPark Floating Rate Capital Ltd. (NYSE:PFLT) Short Interest Up 36.3% in January — source image
Decision brief

The 30-second read

$PFLTBearishMed
01

Why it matters

The rise in short interest indicates traders are betting on a decline, possibly due to recent market volatility or sector-specific concerns.

02

Market read

The news is relevant for traders and investors with exposure to PFLT or the financial sector, suggesting caution in short-term trading.

03

What to watch

Fundamental improvements in PFLT's portfolio or earnings could offset bearish sentiment; macroeconomic factors or interest rate changes might influence the stock independently.

Relevance 6/10Timing: short-term (within 1-2 weeks)

Background

PennantPark Floating Rate Capital Ltd. is a business development company that invests primarily in floating-rate senior loans and other debt instruments.

Company-level read

Ticker impact

$PFLTBearishMedium confidence
Context

The news about increased short interest indicates potential bearish sentiment for PennantPark Floating Rate Capital Ltd.

Expected impact

Moderate decline of 2-4% in the near term if the trend continues, especially if accompanied by other negative technical signals.

Evidence & confidence

The significant increase in short interest points to bearish sentiment, but the mixed analyst ratings and relatively low short-interest ratio (1.4 days) suggest caution in overestimating downside risk.

Market effects

Potential negative impact on the financial sector, particularly for business development companies like PFLT.

Limited regional impact; primarily affecting investors and traders focused on US financials.

Low; the news pertains to a specific US-based financial entity.

Counterpoint

The increase in short interest could be a temporary correction or profit-taking rather than a fundamental concern; the stock may rebound if market conditions improve.

Key entities

  • PennantPark Floating Rate Capital Ltd.

    A business development company focusing on floating-rate debt investments.

Related articles

$PFLTMed

PennantPark Floating Rate Capital Ltd. Announces Financial Results for the Third Quarter Ended June 30, 2026

PennantPark Floating Rate Capital Ltd. (PFLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PennantPark Floating Rate Capital Ltd. Announces Financial Results for the Third Quarter Ended June 30, 2026 MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the third quarter ended

$PFLTMedAI 9/10

PennantPark Floating Rate Capital Ltd. Prices Public Offering of $100 Million 7.375% Notes due 2031

PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) priced a $100 million underwritten public offering of 7.375% notes due 2031, maturing June 15, 2031. The notes may be redeemed starting June 15, 2028 at 100% plus accrued interest. Expected close is about June 1, 2026; an underwriters’ option allows up to $15 million more. Net proceeds will repay its revolving credit facility, fund investments, and support general corporate purposes.

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$NICEMed

NICE cuts 500 jobs as AI reshapes customer-service business

NICE, a customer-service software company, is cutting 5% of its workforce (500 jobs) to adapt to AI-driven changes. It plans to sell its Actimize business, invest in AI, and acquire a German AI startup for $1B. NICE's stock has declined, and revenue is projected to exceed $3B, but earnings may face pressure.